Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-
cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and …

Substantial regressions of metastatic lesions have been observed in up to 70% of patients
with melanoma who received adoptively transferred autologous tumor-infiltrating …

Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …

CD4+ T cells can eliminate tumor cells in vivo in the absence of CD8+ T cells. We have
CD4+ T cells specific for a MHC class II-restricted, tumor-specific peptide derived from a …

Neoantigens are antigens encoded by tumor-specific mutated genes. Studies in the past few
years have suggested a key role for neoantigens in cancer immunotherapy. Here we review …

Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney
cancer have shown that immunological manipulations can mediate the durable regression …

The technological advances occurred in the last few years have led to a great increase in
the number of tumor associated antigens (TAA) that are currently available for clinical …

Compared to other types of tumor vaccines, RNA vaccines have emerged as promising
alternatives to conventional vaccine therapy due to their high efficiency, rapid development …

Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery
(APM) have been described in tumors of different histology. Murine data suggest that defects …